<DOC>
	<DOCNO>NCT02243007</DOCNO>
	<brief_summary>This research study Phase II clinical trial , evaluate combination drug , FOLFIRINOX Gemcitabine/Nab-Paclitaxel , management participant resectable pancreatic cancer prior surgery .</brief_summary>
	<brief_title>Phase II Study Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel Patients With Resectable Pancreatic Cancer</brief_title>
	<detailed_description>Patients fulfill eligibility criterion randomize Arm A Arm B - Treatment administered outpatient basis . - Upon registration participant randomize Arm A ( FOLFIRINOX ) Arm B ( Gemcitabine/nab-Paclitaxel ) . - After completion FOLFIRINOX Gemcitabine/Nab-paclitaxel , participant without progressive disease proceed radiation therapy capecitabine . - Between 2 4 week radiation complete , participant proceed surgical resection pancreatic cancer</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Cytologic histologic proof pancreatic ductal carcinoma require prior study entry . No evidence metastatic disease determine chest CT scan , abdominal CT scan ( MRI gadolinium and/or manganese ) laparoscopy . All patient must stag physical exam , chest CT , abdominal CT intravenous contrast ( abdominal MRI gadolinium and/or manganese ) . Only potentially resectable patient eligible . Potentially resectable define ) extrapancreatic disease , b ) evidence ( CT ) involvement celiac axis SMA , c ) evidence ( CT MRI ) occlusion SMV SMPV confluence , ) evidence gross peritoneal distant metastasis laparoscopy . Patients must 18 year old old . There upper age restriction . ECOG Performance Status 0 1 eligible . Life expectancy great 3 month . Lab Values : ANC ≥ 1500 cells/mm3 Platelet count least 100,000 cells/mm3 . AST ALT ≤2.5 x upper limit normal Total Bilirubin ≤ 5 x upper limit normal patient s/p biliary stenting AND decrease least two time point stenting . Total Bilirubin ≤ 1.5 x upper limit normal biliary stenting do Serum Creatinine ≤1.5mg/dl OR Creatinine Clearance great equal 30ml/min ( estimate Cockroft Gault Equation ) ( 140 age [ yr ] ) ( body wt [ kg ] ) Creatinine clearance male = ———————————— ( 72 ) ( serum creatinine [ mg/dL ] ) Creatinine clearance female = 0.85 x male value The effect radiation develop human fetus know teratogenic . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study treatment plus 30 day last date study drug administration . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Ability understand willingness sign write informed consent document . Patients fulfill follow criterion exclude : The presence metastatic disease image laparoscopy . Serious concomitant systemic disorder incompatible study ( discretion investigator ) , significant cardiac pulmonary morbidity e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 12 month , ongoing infection manifest fever . Pregnant lactating woman . Women childbearing potential either positive pregnancy test ( serum urine ) baseline . ( Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . Any prior chemotherapy radiation treatment patient 's pancreatic tumor . Diagnosis invasive carcinoma ( except basal cell carcinoma/squamous cell carcinoma skin ) within last five year . Carcinoma insitu allow . Other serious uncontrolled medical condition investigator feel might compromise study participation . Unwillingness participate inability comply protocol duration study . Participation investigational drug study within 4 week precede start study treatment . History uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant , preclude informed consent , interfere compliance oral drug intake . Major surgery , exclude laparoscopy , within 4 week start study treatment , without complete recovery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Resectable pancreatic cancer</keyword>
	<keyword>Pancreatic Ductal Carcinoma</keyword>
</DOC>